H1B Salary Data

Home › Employers › Chicagoland Infectious Disease, P.C.

Chicagoland Infectious Disease, P.C.: H-1B salaries and sponsorship

Chicagoland Infectious Disease, P.C. filed 3 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $208,000.

Applications (LCAs)3
Certified3
Employer addressSouth Holland, IL
H-1B dependent employerNo
Median offered salary$208,000
Middle half of salaries$145,600–$208,000
10th–90th percentile$108,160–$208,000

Does Chicagoland Infectious Disease, P.C. sponsor H-1B visas?

Chicagoland Infectious Disease, P.C. filed 3 labor condition applications in fiscal years 2023–2026, the latest submitted on Feb 25, 2026. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.

Salaries by job title

Job titleLCAsMedian salary
Infectious Disease Specialist2$208,000
Healthcare Data Analyst1$83,200

Applications by fiscal year

Fiscal yearLCAsMedian salary
FY20231$208,000
FY20251$83,200
FY20261$208,000

Prevailing wage levels

The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.

Where the jobs are

Occupations

Latest applications

Job titleBase salaryLocationSubmittedStart dateStatus
Infectious Disease Specialist$208,000
Level II
Chicago, ILFeb 25, 2026Jul 1, 2026Certified
Healthcare Data Analyst$83,200
Level I
Homewood, ILSep 24, 2024Nov 1, 2024Certified
Infectious Disease Specialist$208,000Harvey, ILMar 10, 2023Jul 1, 2023Certified

Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).